Adc Therapeutics SA (NYSE:ADCT) has a beta value of 1.60 and has seen 1.37 million shares traded in the last trading session. The company, currently valued at $354.13M, closed the last trade at $3.68 per share which meant it gained $0.52 on the day or 16.46% during that session. The ADCT stock price is -64.13% off its 52-week high price of $6.04 and 90.22% above the 52-week low of $0.36. The 3-month trading volume is 774.52K shares.
Adc Therapeutics SA (NYSE:ADCT) trade information
Sporting 16.46% in the green in last session, the stock has traded in the green over the last five days, when the ADCT stock price touched $3.68 or saw a rise of 0.27%. Year-to-date, Adc Therapeutics SA shares have moved 121.69%, while the 5-day performance has seen it change 36.80%. Over the past 30 days, the shares of Adc Therapeutics SA (NYSE:ADCT) have changed 6.98%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adc Therapeutics SA (ADCT) estimates and forecasts
Figures show that Adc Therapeutics SA shares have outperformed across the wider relevant industry. The company’s shares have gained 131.45% over the past 6 months, with this year growth rate of 34.69%, compared to 15.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 84.52% over the past 5 years. Earnings growth for 2024 is a modest 35.76% while over the next 5 years, the company’s earnings are expected to increase by 15.80%.
ADCT Dividends
Adc Therapeutics SA is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
